SCHEMBL14409697

SCHEMBL14409697

CC1CCC(CN2CCN(C)CC2)CC1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.55
CHRM5 P08912 1/20 0.41
ADRA2C P18825 1/20 0.41
CACNA2D1 P54289 1/20 0.37
CACNA1B Q00975 1/20 0.37
CACNB1 Q02641 1/20 0.37
CACNA1C Q13936 1/20 0.37
NCF1 P14598 1/20 0.37
CARM1 Q86X55 1/20 0.36
PRMT6 Q96LA8 1/20 0.36
PRMT1 Q99873 1/20 0.36
PRMT8 Q9NR22 1/20 0.36
WNT1 P04628 1/20 0.32
GSK3B P49841 1/20 0.32
DYRK1A Q13627 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13981150 1.00 ACHE (0.55) ACHECHRM5ADRA2CCACNA2D1CACNA1B
SCHEMBL26762470 0.96 ACHE (0.57) ACHECHRM5ADRA2CCACNA2D1CACNA1B
SCHEMBL26762465 0.94 ACHE (0.53) ACHECHRM5ADRA2CCACNA2D1CACNA1B
SCHEMBL4401614 0.91 CHRM5 (0.48) ACHECHRM5ADRA2CCACNA2D1CACNA1B
SCHEMBL26762595 0.88 ACHE (0.52) ACHECHRM5ADRA2CCACNA2D1CACNA1B
SCHEMBL15499060 0.88 ACHE (0.42) ACHECHRM5ADRA2CCACNA2D1CACNA1B
SCHEMBL25959923 0.85 ACHE (0.46) ACHECHRM5ADRA2CCACNA2D1CACNA1B
SCHEMBL26762522 0.85 ACHE (0.50) ACHECHRM5ADRA2CCARM1PRMT6
SCHEMBL15217800 0.84 CHRM5 (0.43) ACHECHRM5ADRA2CCACNA2D1CACNA1B
SCHEMBL3436997 0.84 NCF1 (0.52) ACHECHRM5ADRA2CCACNA2D1CACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023023255-A1 BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES AND THERAPEUTIC USE THEREOF NURIX THERAPEUTICS, INC. (US) 2023-02-23 WO disclosed
WO-2022266249-A1 KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX, INC. (US) 2022-12-22 WO disclosed
EP-3943086-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF BioSplice Therapeutics, Inc. (US) 2022-01-26 EP disclosed
EP-3448838-B1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF BIOSPLICE THERAPEUTICS INC (US) 2021-08-11 EP disclosed
US-20160366909-A1 OLIGOSACCHARIDE COMPOSITIONS FOR USE AS ANIMAL FEED AND METHODS OF PRODUCING THEREOF MIDORI USA, INC. (US) 2016-12-22 US disclosed
US-20160032038-A1 POLYMERIC IONIC SALT CATALYSTS AND METHODS OF PRODUCING THEREOF MIDORI USA, INC. (US) 2016-02-04 US disclosed
US-9238845-B2 Methods of producing sugars from biomass feedstocks MIDORI USA, INC. (US) 2016-01-19 US disclosed
US-20160007642-A1 OLIGOSACCHARIDE COMPOSITIONS AND METHODS FOR PRODUCING THEREOF MIDORI USA, INC. (US) 2016-01-14 US disclosed
US-20150202607-A1 POLYMERIC AND SOLID-SUPPORTED CATALYSTS, AND METHODS OF DIGESTING CELLULOSIC MATERIALS USING SUCH CATALYSTS Midori Renewables, Inc. (US) 2015-07-23 US disclosed
WO-2014159558-A1 POLYMERIC IONIC SALT CATALYSTS AND METHODS OF PRODUCING THEREOF Midori Renewables, Inc. (US) 2014-10-02 WO disclosed
US-20140060522-A1 METHODS OF PRODUCING SUGARS FROM BIOMASS FEEDSTOCKS HERCULES CAPITAL, INC. 2014-03-06 US disclosed
US-8507484-B2 Preventive and/or therapeutic agent for neutrophilic inflammatory diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-08-13 US disclosed
US-8507484-B2 Preventive and/or therapeutic agent for neutrophilic inflammatory diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2013-08-13 US disclosed
US-20070213361-A1 Preventive and/or therapeutic agent for neutrophilic inflammatory diseases KYOWA KIRIN CO., LTD. (JP) 2007-09-13 US disclosed
US-20070213361-A1 Preventive and/or therapeutic agent for neutrophilic inflammatory diseases KYOWA KIRIN CO., LTD. (JP) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160366909-A1 OLIGOSACCHARIDE COMPOSITIONS FOR USE AS ANIMAL FEED AND METHODS OF PRODUCING THEREOF FUT5, FUT6, OSTC ACHE 3795/4885CHRM5 3655/4885ADRA2C 4113/4885
US-20070213361-A1 Preventive and/or therapeutic agent for neutrophilic inflammatory diseases MPO, MSR1, NR4A3 ACHE 2154/4885CHRM5 822/4885ADRA2C 1301/4885
US-20150202607-A1 POLYMERIC AND SOLID-SUPPORTED CATALYSTS, AND METHODS OF DIGESTING CELLULOSIC MATERIALS USING SUCH CATALYSTS MGAM, CEL, SI ACHE 504/4885CHRM5 3686/4885ADRA2C 4661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.